UBS AM’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

UBS AM’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,057	Closed	-$1.85M	–	2628
2020 Q4	$1.85M	Buy	14,057 +4,700	+50%	+$415K	﹤0.01%	1716
2020 Q3	$473K	Buy	9,357 +5,157	+123%	+$232K	﹤0.01%	2172
2020 Q2	$200K	Buy	+4,200	New	+$195K	﹤0.01%	2388
2019 Q4	–	Sell	-64	Closed	-$2.3K	–	2919
2019 Q3	$2.3K	Hold	64	–	–	﹤0.01%	2852
2019 Q2	$1.99K	Buy	+64	New	+$1.74K	﹤0.01%	2828

UBS AM's EIDX Position: Q1 2021 in Review

UBS AM sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 14,057 shares — an estimated $1.85M sold.

UBS AM first reported a position in EIDX in Q2 2019 and held it in 5 quarters. The position peaked at $1.85M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

UBS AM reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
UBS AM sold 14,057 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.85M.
UBS AM first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
UBS AM's Eidos Therapeutics, Inc. Common Stock position peaked at $1.85M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on UBS AM's 13F filing for Q1 2021, filed 14 May 2021.